Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by IrishCanuckon Aug 12, 2021 11:43am
190 Views
Post# 33691846

RE:RE:RE:RE:RE:Key Takeaways From Stauffer and Dan

RE:RE:RE:RE:RE:Key Takeaways From Stauffer and DanAnyone giving you a number for WOMAC pain relief estimates against placebo is a scam artist. There's no way to estimate that beforehand. Of course it's going to be compared to Naproxen, just like it's going to be compared to Celebrex, non-selective NSAIDs and others, but that's not what the Phase 2 is designed to test. 

Look man, you may think these are legitimate questions but you're clearly fearmongering. If anyone had these answers they wouldn't be doing clinical trials, they could skip to the end. But the whole point of clinical trials are to figure these questions out. That's not the company's fault for not knowing these things yet. The point of AME was to de-risk Phase 3 so technically this was a good thing to do before running into failure with 150mg during Phase 3. So you're not going any points of superiority pointing these questions out on Stockhouse. 


PlaySafe wrote: What is your confidence level that 75mg will be statistically signifigant to placebo over a two week period?  And the WOMAC scores of the 75mg trial will be compared to the WOMAC scores of Naproxen so even though the Phase 2 doesn't compare Antibe's drug to Naproxen you can't get away with comparing the WOMAC with previous NSAID studies.  Furthermore what is your confidence level of a 12 week phase 3 study and not seeing any anomolies in liver levels?  In other words do you think that the Antibe scientists know exactly the long term impact of their molecule?  If they did then they would have known to try lover doses during their Phase 2 trials and would have anticipated the AME issue.


<< Previous
Bullboard Posts
Next >>